IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer
The ability of IL-15 to enhance NEO-201 efficacy, with NK cells as effectors, supports the hypothesis of combining NEO-201 and IL-15 with NK cell therapy (i.e. IL-15-secreting CAR-NK cells with a longer IL-15 <i>in vivo</i> half-life and stronger NK activity) for the treatment of gynecological cancers expressing O-glycans recognized by NEO-201.
Authors
- Maggie C. Cam (ORCID: https://orcid.org/0000-0001-8190-9766)
- Massimo Fantini (ORCID: https://orcid.org/0000-0002-8164-2587)
- Maria Pia Morelli (ORCID: https://orcid.org/0009-0000-9543-6584)
- Christina M. Annunziata (ORCID: https://orcid.org/0000-0003-2033-6532)
- K. Y. Tsang (ORCID: https://orcid.org/0000-0002-2546-1108)
- Soumya Korrapati
- Elijah F. Edmondson (ORCID: https://orcid.org/0000-0002-6106-3705)
- Philip M. Arlen
- L. Dena G. Hernandez
- Jamie Hur
- Mayank tandon
- Christopher B. Cole
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- Precision BioLogic (Canada) (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.3389/fimmu.2026.1652596
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Southern California